Soft Tissue Sarcoma Pipeline, Clinical Trials, FDA Approvals, Research and Developments, Future Perspectives, and Companies (Updated)

DelveInsight's, "Soft Tissue Sarcoma Pipeline Insight, 2023," report provides comprehensive insights about 125+ companies and 130+ pipeline drugs in Soft Tissue Sarcoma pipeline landscape. It covers the Soft Tissue Sarcoma pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Soft Tissue Sarcoma pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Key Takeaways from the Soft Tissue Sarcoma Pipeline Report
• DelveInsight's Soft Tissue Sarcoma pipeline report depicts a robust space with 125+ active players working to develop 130+ pipeline therapies for Soft Tissue Sarcoma treatment.
• The leading companies working in the Soft Tissue Sarcoma Market include Advenchen Laboratories, Philogen, Gradalis, Epizyme, Chugai Pharma France, CytRx, Taiho Pharmaceuticals, KaryoPharm Therapeutics, Nanobiotix, Apexigen, Lytix Biopharma, Incyte Corporation, Iovance Biotherapeutics, Aadi Bioscience, Inc., AVEO Pharmaceuticals, Bayer, VasGene Therapeutics, Mirati Therapeutics, Novartis Pharmaceuticals, Incyte Corporation, Tracon Pharmaceuticals, Jiangsu Hengrui Medicine, Exelixis, Qbiotics, AstraZeneca, Loxo Oncology, ImmunityBio, Monopar Therapeutics, Chipscreen Biosciences, Ltd., Agenus, C4 Therapeutics, Inc., Noxopharm Limited, Moleculin Biotech, Inc., Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd., Tracon Pharmaceuticals Inc., Guangdong Xiangxue Precision Medical Technology Co., Ltd., Cornerstone Pharmaceuticals, Takara Bio Inc., Jazz Pharmaceuticals, Lyell Immunopharma, Telix Pharmaceuticals, and others.
• Promising Soft Tissue Sarcoma Pipeline Therapies in the various stages of development include Olaratumab, Pembrolizumab, NBTXR3, Glufosfamide, PXD101, Doxorubicin, and others.
• January 2024: Epizyme Inc. announced a study of Phase 3 clinical trials for Tazemetostat, and Doxorubicin HCl. The participants of this study will have advanced epithelioid sarcoma. Sarcoma is a cancer of the connective tissues, such as nerves, muscles and bones. Epithelioid sarcoma is an ultra-rare sarcoma of the soft-tissue.
• December 2023: Epizyme Inc. announced a study of Phase 3 clinical trials for Tazemetostat and Doxorubicin HCl. The open-label phase 1b portion is designed to evaluate the safety of the combination of tazemetostat + doxorubicin, as well as to establish the maximum tolerated dose (MTD) and the RP3D. The phase 3 portion of the clinical trial aims to compare tazemetostat + doxorubicin to the current front-line standard treatment, single-agent doxorubicin + placebo, when used as first-line treatment in locally advanced unresectable or metastatic ES.
• November 2023: Lytix Biopharma AS announced a study of Phase 2 clinical trials for LTX-315 and TILs. An Open Label Phase II Single Centre Study Investigating the Safety and Efficacy of LTX-315 and Adoptive T-cell Therapy in Patients With Advanced/Metastatic Soft Tissue Sarcoma (ATLAS-IT-04).

Request a sample and discover the recent advances in Soft Tissue Sarcoma Treatment Drugs @ Soft Tissue Sarcoma Pipeline Outlook Report- https://www.delveinsight.com/report-store/soft-tissue-sarcoma-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

In the Soft Tissue Sarcoma pipeline report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Soft Tissue Sarcoma collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Soft Tissue Sarcoma Overview
Soft tissue sarcoma is a disease in which malignant (cancer) cells form in the soft tissues of the body. Having certain inherited disorders can increase the risk of soft tissue sarcoma. A sign of soft tissue sarcoma is a lump or swelling in soft tissue of the body. Soft tissue sarcoma is diagnosed with a biopsy.

Find out more about Soft Tissue Sarcoma Treatment Landscape @ Drugs for Soft Tissue Sarcoma Treatment- https://www.delveinsight.com/sample-request/soft-tissue-sarcoma-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Soft Tissue Sarcoma Emerging Drugs Profile
• AL3818: Advenchen Laboratories
• L19 TNF: Philogen
• Camsirubicin: Monopar Therapeutics

Soft Tissue Sarcoma Pipeline Therapeutics Assessment
There are approx. 125+ key companies which are developing the therapies for Soft Tissue Sarcoma. The Soft Tissue Sarcoma companies which have their Soft Tissue Sarcoma drug candidates in the most advanced stage, i.e. phase III include, Advenchen Laboratories, LLC.

DelveInsight's Soft Tissue Sarcoma pipeline report covers around 130+ products under different phases of clinical development like
• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

Soft Tissue Sarcoma pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
• Oral
• Parenteral
• Intravenous
• Subcutaneous
• Topical.

Soft Tissue Sarcoma Pipeline Products have been categorized under various Molecule types such as
• Monoclonal Antibody
• Peptides
• Polymer
• Small molecule
• Gene therapy

Learn more about the emerging Soft Tissue Sarcoma Pipeline Therapies @ Soft Tissue Sarcoma Clinical Trials Assessment- https://www.delveinsight.com/sample-request/soft-tissue-sarcoma-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Scope of the Soft Tissue Sarcoma Pipeline Report
• Coverage- Global
• Soft Tissue Sarcoma Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
• Soft Tissue Sarcoma Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
• Soft Tissue Sarcoma Companies- Advenchen Laboratories, Philogen, Gradalis, Epizyme, Chugai Pharma France, CytRx, Taiho Pharmaceuticals, KaryoPharm Therapeutics, Nanobiotix, Apexigen, Lytix Biopharma, Incyte Corporation, Iovance Biotherapeutics, Aadi Bioscience, Inc., AVEO Pharmaceuticals, Bayer, VasGene Therapeutics, Mirati Therapeutics, Novartis Pharmaceuticals, Incyte Corporation, Tracon Pharmaceuticals, Jiangsu Hengrui Medicine, Exelixis, Qbiotics, AstraZeneca, Loxo Oncology, ImmunityBio, Monopar Therapeutics, Chipscreen Biosciences, Ltd., Agenus, C4 Therapeutics, Inc., Noxopharm Limited, Moleculin Biotech, Inc., Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd., Tracon Pharmaceuticals Inc., Guangdong Xiangxue Precision Medical Technology Co., Ltd., Cornerstone Pharmaceuticals, Takara Bio Inc., Jazz Pharmaceuticals, Lyell Immunopharma, Telix Pharmaceuticals, and others.
• Soft Tissue Sarcoma Pipeline Therapies- Olaratumab, Pembrolizumab, NBTXR3, Glufosfamide, PXD101, Doxorubicin, and others.

Dive deep into rich insights for new drugs for Soft Tissue Sarcoma treatment, Visit @ Soft Tissue Sarcoma Market Drivers and Barriers, and Future Perspective- https://www.delveinsight.com/sample-request/soft-tissue-sarcoma-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Table of Content
1. Introduction
2. Executive Summary
3. Soft Tissue Sarcoma: Overview
4. Pipeline Therapeutics
5. Therapeutic Assessment
6. Soft Tissue Sarcoma - DelveInsight's Analytical Perspective
7. Late Stage Products (Phase III)
8. Anlotinib: Advenchen Laboratories, LLC
9. Drug profiles in the detailed report…..
10. Mid Stage Products (Phase II)
11. Camsirubicin: Monopar Therapeutics
12. Drug profiles in the detailed report…..
13. Early Stage Products (Phase I)
14. FHD-609: Foghorn Therapeutics
15. Drug profiles in the detailed report…..
16. Inactive Products
17. Soft Tissue Sarcoma Key Companies
18. Soft Tissue Sarcoma Key Products
19. Soft Tissue Sarcoma- Unmet Needs
20. Soft Tissue Sarcoma- Market Drivers and Barriers
21. Soft Tissue Sarcoma- Future Perspectives and Conclusion
22. Soft Tissue Sarcoma Analyst Views
23. Soft Tissue Sarcoma Key Companies
24. Appendix

For further information on the Soft Tissue Sarcoma Pipeline Therapeutics, reach out @ Soft Tissue Sarcoma Unmet Needs and Analyst Views- https://www.delveinsight.com/sample-request/soft-tissue-sarcoma-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

List of Important Published Links-

https://forum.eset.com/profile/88964-denny-dones/?tab=field_core_pfield_11
https://en.pinkoi.com/user/gg_116344212900924579142
https://dennydones9.diary.ru/
https://slideslive.com/ewkwsgtt7o?tab=about
https://dennydones.substack.com/p/behcets-syndrome-market-size-in-the?r=33xju7&utm_campaign=post&utm_medium=web
https://scocial-online.mn.co/posts/46864423
https://akb.tribe.so/post/behcet-s-disease-a-rare-and-chronic-inflammatory-condition-has-long-posed-c--6576dd3288d020256754898b
https://www.sutori.com/en/denny-dones?tab=profile
https://network-96590.mn.co/posts/46865392
https://lean-in-bay-area.mn.co/posts/46865790
https://network-88594.mn.co/posts/46865905
https://decide.mn.co/posts/46866036
https://jomijomig.mn.co/posts/46866708
https://constantlycheeky.mn.co/posts/46867239
https://www.vwvortex.com/members/ybhardwaj.3957496/#about
https://redline-rp.mn.co/posts/46868784
https://network-1588972.mn.co/posts/advancements-and-challenges-in-the-metastatic-melanoma-market
https://thecircle360.mn.co/posts/47424666
https://togethers.mn.co/posts/47424994
https://moneyschoolinc.mn.co/posts/47425167
https://renaissance.mn.co/posts/47425340
https://www.gamemaps.com/profile/1258006
https://presenceofeden.mn.co/posts/47426181
https://thecleverbeaver.mn.co/posts/47426376
https://network-1033912.mn.co/posts/47426607
https://music-producers.mn.co/posts/47426714
https://healingtheinnerme.mn.co/posts/47426814
https://caribbeanonelove.mn.co/posts/47427255
https://ultrasbook.mn.co/posts/47427170
https://voz.vn/u/dennydones99.1954229/#about
https://www.avsforum.com/members/dennydones99.9714847/#about
https://club-elixir.mn.co/posts/47495566
https://ceo-codes.mn.co/posts/47495634
https://skouting.mn.co/posts/47495827
https://network-1311522.mn.co/posts/47495953
https://network-21603.mn.co/posts/47496087
https://jobs.blooloop.com/employers/2614577-delveinsight
https://network-90617.mn.co/posts/47497231
https://www.gn2.poli.ufrj.br/profile/dennydones99/profile
https://vibe-hangout.mn.co/posts/47497589
https://englishclub.mn.co/posts/47497804
https://www.social-vape.com/read-blog/99678
https://hanson.net/users/dennydones99
https://app.scholasticahq.com/scholars/248575-denny-dones
https://credibleleaders.mn.co/posts/47499537
https://network-64869.mn.co/posts/47499548
https://agario-game-org.mn.co/posts/47500134
https://beermapping.com/account/dennydones99
https://caydenbook.mn.co/posts/adeno-associated-virus-vectors-in-gene-therapy-market-size-and-outlook-report-2032
https://rdd-rapter-gameing.mn.co/posts/adeno-associated-virus-vectors-in-gene-therapy-market-outlook-report-2032
https://www.pozible.com/profile/denny-dones
https://www.charitywater.org/denny-dones
https://pologics.mn.co/posts/47645227
https://network-75595.mn.co/posts/47645350
https://futurewear.mn.co/posts/47645511
https://forum.instube.com/u/johnsmithnevadaus9
https://www.pixiv.net/en/users/101730403
https://platform.wegohealth.com/forum/t/monoclonal-gammopathy-of-undetermined-significance-market-insight-epidemiology-and-market-forecast-2032/1175
https://network-483739.mn.co/posts/47647105
https://unplugfromthematrix.mn.co/posts/47647275
https://diy-vision.mn.co/posts/47647380
https://network-6570.mn.co/posts/47647667
https://jobs.thetab.com/employers/1458246-delveinsight
https://careero.mn.co/posts/47652643
https://fromfostercaretoceo.mn.co/posts/47652747
https://www.remotehub.com/denny.dones
https://vibe-3-0.mn.co/posts/monoclonal-gammopathy-of-undetermined-significance-market-insight-epidemiology-and-market-forecast
https://gamingnetwork.mn.co/posts/47654203
https://lgbtgia-chat.mn.co/posts/47654443
https://network-49642.mn.co/posts/47654787
https://vaynernation.mn.co/posts/47708020
https://network-68818.mn.co/posts/47708234
https://network-96638.mn.co/posts/47708353
https://machineintelligence.mn.co/posts/methicillin-resistant-staphylococcus-aureus-market-insight-epidemiology-and-market-forecast-2032
https://www.wpanet.org/profile/ybhardwaj/profile
https://antekk.mn.co/posts/47709117
https://www.noteflight.com/profile/101e63d196889e9ea41b68375ecaa38bf5d46aba
https://roosterteeth.com/g/post/82b171a2-75fb-44d1-8131-6b3628b62658
https://friendsgroup.mn.co/posts/47710599
https://network-30.mn.co/posts/47710918
https://keywebco.mn.co/posts/methicillin-resistant-staphylococcus-aureus-market-size-and-outlook-report-2032
https://network-19115.mn.co/posts/47711333
https://teacher-dot-network.mn.co/members/20931428
https://inclusionbusiness.mn.co/posts/47712828
https://snapped.mn.co/posts/methicillin-resistant-staphylococcus-aureus-market-research-report
https://mylook-online.mn.co/posts/47753600
https://pig-landtin.mn.co/posts/47753674
https://the-e-group-club.mn.co/posts/47754907
https://playeur.com/u/dennydones99
https://profitfirst.mn.co/posts/47757615
https://chatclub.mn.co/posts/47757715
https://visbn.mn.co/posts/advancements-in-perivascular-epithelioid-cell-tumor-market-current-trends-and-future-prospects
https://globalaffairs.mn.co/posts/perivascular-epithelioid-cell-tumor-market-insight-epidemiology-and-market-forecast-2032
https://for-the-dolers.mn.co/posts/47758103
https://click-funnels.mn.co/posts/47763706
https://mt2.org/uyeler/dennydones99.12436/#about
https://blogger-mania.mn.co/posts/47769537
https://kyte-en-espanol.mn.co/posts/47770089
https://network-4526.mn.co/posts/47769942
https://realfirefighters.mn.co/posts/47769768
https://wanneroo-social.mn.co/posts/advancements-in-hydrocephalus-treatment-market-a-comprehensive-overview
https://network-504797.mn.co/posts/47835298
https://tdcommunitynetworks.mn.co/posts/47835354
https://beyondher.mn.co/posts/47835423
https://edunet.mn.co/posts/47835672
https://tbc-coin.mn.co/posts/47835768
https://www.wanikani.com/users/dennydones999
https://cigarbook.mn.co/posts/47841666
https://imgpile.com/dennydones999

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: ybhardwaj@delveinsight.com
Phone: 9193216187
Address: 304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/report-store/peripheral-nerve-repair-devices-market

This release was published on openPR.